 Affimed NV NASDAQ:AFMD has announced interim clinical results from the investigator-initiated Phase 12 study evaluating cbNK cells pre-complexed with Affimeds innate cell engager ICE AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13. 